60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
1.170
-0.080 (-6.40%)
At close: Jul 31, 2026, 4:00 PM EDT
1.080
-0.090 (-7.69%)
Pre-market: Aug 3, 2026, 4:15 AM EDT
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $162.09K in the quarter ending March 31, 2026, a decrease of -36.75%. This brings the company's revenue in the last twelve months to $1.31M, up 63.89% year-over-year. In the year 2025, 60 Degrees Pharmaceuticals had annual revenue of $1.41M with 106.81% growth.
Revenue (ttm)
$1.31M
Revenue Growth
+63.89%
P/S Ratio
2.37
Revenue / Employee
$438,301
Employees
3
Market Cap
3.11M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.41M | 727.75K | 106.81% |
| Dec 31, 2024 | 681.35K | 427.77K | 168.70% |
| Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
| Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
| Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HCW Biologics | 6.59M |
| Ensysce Biosciences | 4.71M |
| Onconetix | 735.20K |
| Jupiter Neurosciences | 40.45K |
| Creative Medical Technology Holdings | 3.00K |
| Ernexa Therapeutics | 1,000.00 |
SXTP News
- 3 days ago - 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 days ago - 60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026 - GlobeNewsWire
- 25 days ago - 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Proxy statement: Proxy filing - Filings
- 4 weeks ago - 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Slides: Investor presentation - Filings
- 7 weeks ago - 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - GlobeNewsWire
- 7 weeks ago - 60 Degrees Pharmaceuticals Proxy statement: Proxy filing - Filings